Brief: Sonnet Biotherapeutics Enters Into Licensing Agreement With Alkem Laboratories

Sonnet Biotherapeutics Holdings

09/10/2024 14:07

Oct 9 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS INC. ENTERS INTO LICENSING
AGREEMENT WITH
ALKEM LABORATORIES LIMITED TO DEVELOP AND COMMERCIALIZE SON-080
FOR DIABETIC PERIPHERAL NEUROPATHY (DPN) IN INDIA
    * SONNET BIOTHERAPEUTICS HOLDINGS INC: TO RECEIVE $1.0
MILLION IN
UPFRONT PAYMENT AND UP TO AN ADDITIONAL $1.0 MILLION IN
MILESTONE PAYMENTS
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - ALKEM TO FUND,
DEVELOP,
COMMERCIALIZE SON-080 FOR DPN IN INDIA
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - ENTITLED TO RECEIVE
LOW
DOUBLE-DIGIT ROYALTY ON NET SALES OF SON-080

Source text for Eikon:  ID:nGNXbzv78B 
Further company coverage:  SONN.O 

 ((Reuters.Briefs@thomsonreuters.com;))